Some New ESRD Drugs Would Get Two-Year Transition To Medicare Bundling – CMS Plan
This article was originally published in The Pink Sheet Daily
Injectable drugs and biologics that don’t yet fit into existing categories for bundled physician payment would get separate reimbursement for at least two years, CMS proposes.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.